Literature DB >> 7698069

Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies.

M Strolin Benedetti1, P Dostert.   

Abstract

Animal studies have demonstrated that the mouse and rabbit are far more responsive to the inductive properties of rifamycin derivatives than the rat and guinea pig. The rat hepatic cytochrome P450 system seems to be resistant to the action of rifampicin unless very high doses are used. Mouse hepatic microsomal mixed-function oxidase activity is markedly increased by repeated dosing with rifampicin, whereas administration of rifabutin may be ineffective. In humans, both rifampicin and rifabutin are extensively metabolized and induce their own metabolism. The induced metabolic pathways remain essentially unknown. Under autoinduction conditions, the elimination half-life of rifampicin decreases, whereas that of rifabutin is not altered. Although the effects of repeated administration of rifampicin and rifabutin on the various forms of cytochrome P450 in humans have not been extensively examined, there is convincing evidence that the P4503A subfamily is induced by either drug, whereas the P4501A subfamily and P4502D6 do not appear to be affected by rifampicin. Limited reliable information is available concerning the induction of human glucuronyltransferase activities by rifampicin and rifabutin which, however, do not seem to influence zidovudine glucuronide formation in healthy subjects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7698069      PMCID: PMC1566786          DOI: 10.1289/ehp.94102s9101

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  43 in total

1.  [Separation, determination and pharmacokinestics of rifampicin and its biotransformation products].

Authors:  K Winsel; H Iwainsky; E Werner; H Eule
Journal:  Pharmazie       Date:  1976       Impact factor: 1.267

2.  Induction and inhibition of hepatic drug metabolizing enzymes by rifampin.

Authors:  D Pessayre; P Mazel
Journal:  Biochem Pharmacol       Date:  1976-04-15       Impact factor: 5.858

3.  [Comparative study of hepatic bilirubin and paranitrophenol glucuronyl transferase activity. 3. Effect of rifampicin alone or associated with streptomycin and isoniazid in man].

Authors:  J Hakim; G Feldmann; P Boivin; H Troube; J Boucherot; J Penaud; P Guibout; B Kreis
Journal:  Pathol Biol (Paris)       Date:  1973-03

4.  Metabolic study and controlled clinical trials of rifampin.

Authors:  S Sunahara; H Nakagawa
Journal:  Chest       Date:  1972-06       Impact factor: 9.410

5.  Comparison of beta-naphthoflavone and 3-methylcholanthrene as inducers of hepatic cytochrome(s) P-448 and aryl hydrocarbon (benzo[a]pyrene) hydroxylase activity.

Authors:  A R Boobis; D W Nebert; J S Felton
Journal:  Mol Pharmacol       Date:  1977-03       Impact factor: 4.436

6.  Induction of the unspecific microsomal hydroxylase in the human liver.

Authors:  H Remmer; B Schoene; R A Fleischmann
Journal:  Drug Metab Dispos       Date:  1973 Jan-Feb       Impact factor: 3.922

7.  Effect of rifampicin treatment on the metabolism of oestradiol and 17alpha-ethinyloestradiol by human liver microsomes.

Authors:  H M Bolt; H Kappus; M Bolt
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of rifampicin.

Authors:  G Acocella
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

Review 9.  Drug glucuronidation in humans.

Authors:  J O Miners; P I Mackenzie
Journal:  Pharmacol Ther       Date:  1991       Impact factor: 12.310

10.  Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea-pig hepatocytes.

Authors:  A M Jezequel; F Orlandi; L T Tenconi
Journal:  Gut       Date:  1971-12       Impact factor: 23.059

View more
  23 in total

1.  Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.

Authors:  Richard A Graham; Cornelis E C A Hop; Marie T Borin; Bert L Lum; Dawn Colburn; Ilsung Chang; Young G Shin; Vikram Malhi; Jennifer A Low; Mark J Dresser
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin.

Authors:  X G Liu; P K Narang; R C Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

Review 4.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

5.  Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole.

Authors:  C B Trapnell; C Jamis-Dow; R W Klecker; J M Collins
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.

Authors:  Noton K Dutta; Peter B Illei; Charles A Peloquin; Michael L Pinn; Khisimuzi E Mdluli; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2012-04-30       Impact factor: 5.191

7.  Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV.

Authors:  G J Moyle; N E Buss; T Goggin; P Snell; C Higgs; D A Hawkins
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

8.  Assessment of temporal biochemical and gene transcription changes in rat liver cytochrome P450: utility of real-time quantitative RT-PCR.

Authors:  Federico M Goodsaid; Jairam R Palamanda; Diana Montgomery; George Mandakas; Chunyan Gu; Zhiling Li; Xiaoli You; Laura Norton; Roger Smith; Inhou Chu; Tony Soares; Kevin Alton; Narendra S Kishnani; I Y Rosenblum
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

9.  Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.

Authors:  Kelly Dooley; Charles Flexner; Judith Hackman; Charles A Peloquin; Eric Nuermberger; Richard E Chaisson; Susan E Dorman
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

10.  Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers.

Authors:  J G Gillum; J M Sesler; V L Bruzzese; D S Israel; R E Polk
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.